|

Neural Correlates of Motor and Psychiatric Fluctuations in Parkinson's Disease

RECRUITINGSponsored by University Hospital, Geneva
Actively Recruiting
SponsorUniversity Hospital, Geneva
Started2025-06-01
Est. completion2027-12-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted

Summary

This study explores the electrophysiological mechanisms underlying motor and non-motor fluctuations (NMF) in Parkinson's disease (PD), focusing on cortical and subthalamic dynamics during acute dopaminergic stimulation. PD is characterized by both motor symptoms and disabling non-motor symptoms-including neuropsychiatric fluctuations that remain poorly understood. While local field potentials (LFP) recorded from the subthalamic nucleus (STN) via deep brain stimulation (DBS) have revealed beta-band abnormalities linked to motor dysfunction, little is known about the oscillatory signatures of NMF. Preliminary data from our group suggested that gamma-band EEG activity in frontotemporal regions may correlate with neuropsychiatric fluctuations. This Swiss, two-center, prospective observational study aims to investigate resting-state electroencephalogram (EEG) and STN-LFP correlates of motor and non-motor symptoms during a modified levodopa challenge in 30 PD patients with STN-DBS. Using high-density EEG and chronically implanted Medtronic Percept™ DBS devices, electrophysiological data will be collected across five clinical states (combinations of ON/OFF levodopa and DBS). Clinical symptoms will be assessed alongside electrophysiological activity to identify frequency-specific cortical-STN biomarkers. Machine learning models (e.g., LASSO regression) will be used to predict motor and non-motor states from EEG and LFP data, enabling the identification of dynamic oscillatory markers. This could inform future adaptive DBS strategies. The study leverages advanced methods in neurophysiology, imaging, and machine learning to deepen our understanding of PD fluctuations. It also proposes the first detailed electrophysiological mapping of NMF, which could improve patient stratification and neuromodulation therapies. Anatomical validation of DBS lead placement will be performed using standard neuroimaging toolkits.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

* Diagnosis of Parkinson's disease (PD) based on United Kingdom Parkinson's Disease Society Brain Bank Criteria.
* Patients candidate for STN-DBS in the PD phase called fluctuations stage.
* Presence of fluctuations (motor and/or non-motor) are based on the pre-surgical DBS assessment:
* To be on dopaminergic therapy.
* Patients who have undergone STN-DBS implantation within 4 to 8 weeks before electrophysiological acquisition.

Exclusion Criteria:

* Patients with an age greater than 80 years,
* Dementia (defined by a MOCA score ≤24),
* Active psychosis or depression with suicidal ideation,
* Any clinically meaningful non-stable physical diseases,
* Patients with OFF-drug state so severe that it prevents study tests from being carried out (e.g acute painful dystonia, intolerable non-motor symptoms such as pain, anxiety),
* Participating in a pharmacological study,
* Inability to provide informed consent (legal guardianship).

Conditions2

PARKINSON DISEASE (Disorder)Parkinson's Disease

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.